Jpmorgan Chase & CO Acumen Pharmaceuticals, Inc. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Acumen Pharmaceuticals, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 63,066 shares of ABOS stock, worth $149,466. This represents 0.0% of its overall portfolio holdings.
Number of Shares
63,066
Previous 17,877
252.78%
Holding current value
$149,466
Previous $43,000
262.79%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding ABOS
# of Institutions
78Shares Held
41.8MCall Options Held
57.7KPut Options Held
749K-
Ra Capital Management, L.P. Boston, MA14.9MShares$35.4 Million0.52% of portfolio
-
Franklin Resources Inc San Mateo, CA3.55MShares$8.41 Million0.0% of portfolio
-
Sands Capital Ventures, LLC Arlington, VA3.42MShares$8.1 Million4.37% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD2.3MShares$5.45 Million0.19% of portfolio
-
Black Rock Inc. New York, NY2.16MShares$5.12 Million0.0% of portfolio
About Acumen Pharmaceuticals, Inc.
- Ticker ABOS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,503,100
- Market Cap $96M
- Description
- Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Ph...